1737 related articles for article (PubMed ID: 33824268)
1. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
2. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP; Rajendran RL; Khan F; Dmello C; Gangadaran P; Ahn BC
Front Immunol; 2022; 13():925985. PubMed ID: 35936003
[TBL] [Abstract][Full Text] [Related]
3. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
4. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
5. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
6. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
Li Y; Hu Z; Li Y; Wu X
Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
8. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
9. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
Front Immunol; 2022; 13():830292. PubMed ID: 35211124
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
[TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
14. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
15. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
17. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
18. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
19. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
20. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
